Endoscopic management of Mirizzi’s syndrome

R E England, D F Martin

Abstract

Background—The accepted management of Mirizzi’s syndrome is surgical, but endoscopic and percutaneous management have been described.

Aim—To review our experience of endoscopic intervention for Mirizzi’s syndrome.

Patients and Methods—ERCP reports of patients presenting for endoscopic management of choledocholithiasis between March 1989 and June 1995 were reviewed. Those with cholangiographic evidence of Mirizzi’s syndrome were selected for study. Patient records and cholangiograms were reviewed and follow up was recorded from the notes or by telephone contact with patients, their relatives, or doctors.

Results—Twenty five patients had Mirizzi’s syndrome. Sixteen were female and their median age was 67 years (range 28–91). Ten presented with painless jaundice, nine with painful jaundice, four with cholangitis, and two had pain as their only symptom. Twelve were referred for surgery and 11 of these had preliminary endoscopic therapy. Thirteen have been treated solely with endoscopic therapy. Treatment in this group was aimed at relieving jaundice and removing stones. Stones were completely removed in three patients. Nine patients have been treated with long term stents, and one awaits extracorporeal shockwave lithotripsy of the gall bladder. Complications of treatment occurred in four of 25 after ERCP.

Conclusions—Endoscopic treatment of Mirizzi’s syndrome is effective as a temporising measure before surgery and can be definitive treatment for unsuitable surgical candidates.

Keywords: Mirizzi’s syndrome, ERCP, endoscopic therapy.

Mirizzi’s syndrome was described in 1948 and consists of a stone impacted in the neck of the gall bladder or in the cystic duct, causing inflammation and extrinsic compression of the common duct, leading to obstructive jaundice. Mirizzi’s syndrome may be subdivided into types I and II: in the first there is extrinsic compression of the common duct by an inflamed or enlarged gall bladder (Fig 1) while in type II the stone erodes from the gall bladder or the cystic duct into the common duct resulting in a cholecystocholedochal fistula (Fig 2). The syndrome is rare occurring in only 0.7–1.1% of patients undergoing cholecys-

Gut 1997; 40: 272–276

Figure 1: Retrograde cholangiogram showing extrinsic compression of the common duct with dilatation of the biliary tree upstream – Mirizzi type I.
Results

Twenty five patients had a cholangiographic diagnosis of Mirizzi's syndrome. Sixteen were female and the median age was 67 years (range 28–91). Ten presented with painless jaundice, nine with pain and jaundice, four with cholangitis, and two had pain as their only symptom. None presented with a clinical diagnosis of acute cholecystitis and in only one was the diagnosis of Mirizzi syndrome suspected on preliminary sonography. At ERCP 16 had Mirizzi type I, with a stone impacted in the neck of the gall bladder (7) or cystic duct (9). Stone size (corrected for magnification) was a median of 1.5 cm (range 0.75–2.25). Nine patients had Mirizzi type II with a biliary fistula between the wall of the gall bladder and the common duct (5), or the cystic duct and the common duct (4). Stone size was larger, median 2.25 cm (range 1.12–5.25). There were coincidental common bile duct stones in only one patient.

Where patients were medically fit they were referred for definitive surgical treatment (12 of 25), and their clinical details are given in Table I. Thirteen of 25 were treated solely with endoscopic therapy, and their details are given in Table II. Most of this group were elderly or unfit for surgery, or both.

Of the 12 patients referred for surgical therapy 11 had preliminary endoscopic therapy. Ten had Mirizzi type I. One patient (case 8), presenting with pain alone, had Mirizzi type I diagnosed on retrograde cholangiography with extrinsic compression of the common hepatic duct by a distended gall bladder with mild dilatation of the intrahepatic biliary radicals. As the patient had not developed jaundice by the time of the initial ERCP no endoscopic drainage was performed and she was referred directly for surgery. She remained well (without jaundice) for the subsequent year before an elective cholecystectomy. Her inclusion in this series was on the basis of her cholangiographic and subsequent surgical findings: she required open conversion of a laparoscopic procedure because of two impacted stones in Hartmann’s pouch. Her lack of jaundice despite the cholangiographic findings must be explained by incomplete obstruction of the biliary tree. In two patients (cases 9 and 25) endoscopic sphincterotomy was the only treatment: case 25 had previously had sphincterotomy for common bile duct stones and presented with pain alone and was referred for surgery. In case 9 attempts to disimpact the stone from the cystic duct failed and he was referred for cholecystectomy during the same admission. The remaining patients had biliary drainage

---

**Table 1 Clinical details of the surgically treated group**

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age (y)</th>
<th>Presentation</th>
<th>Mirizzi type</th>
<th>Endoscopic treatment</th>
<th>Surgery</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>4</td>
<td>F</td>
<td>37</td>
<td>Jaundice+pain</td>
<td>Type I</td>
<td>ES, cystic duct disimpacted, ESWL</td>
<td>LC at 15 days</td>
<td>Stone had been fragmented. Alive and well</td>
</tr>
<tr>
<td>8</td>
<td>F</td>
<td>65</td>
<td>Pain</td>
<td>Type I</td>
<td>None</td>
<td>LC converted to OC at 365 days</td>
<td>Surgery recommended. Alive and well</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>56</td>
<td>Jaundice+pain</td>
<td>Type I</td>
<td>ES</td>
<td>OC+CBD exploration at 3 days</td>
<td>Surgery recommended. Alive and well</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>60</td>
<td>Jaundice</td>
<td>Type I</td>
<td>ES, CBD stent</td>
<td>OC at 116 days</td>
<td>Invastive carcinoma of gall bladder on histology and died from this 388 days after cholecystectomy</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>28</td>
<td>Jaundice+pain</td>
<td>Type I</td>
<td>ES, CBD stent</td>
<td>OC+CBD exploration at 1 day</td>
<td>Alive and well</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>65</td>
<td>Cholangitis</td>
<td>Type II</td>
<td>ES, CBD stent, mechanical lithotripsy</td>
<td>OC+CBD exploration at 7 days</td>
<td>No response to endoscopic treatment. Alive and well after surgery</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>70</td>
<td>Jaundice</td>
<td>Type I</td>
<td>CBD stent</td>
<td>OC at 120 days</td>
<td>Alive and well</td>
</tr>
<tr>
<td>17</td>
<td>F</td>
<td>28</td>
<td>Jaundice+pain</td>
<td>Type I</td>
<td>Cystic duct disimpacted, cystic duct stent</td>
<td>OC at 63 days</td>
<td>ES not performed as young and wanted to preserve sphincter. Alive and well</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>59</td>
<td>Cholangitis+renal failure</td>
<td>Type I</td>
<td>ES, CBD stent</td>
<td>OC at 165 days</td>
<td>Surgery postponed till renal failure resolved. Alive and well</td>
</tr>
<tr>
<td>22</td>
<td>F</td>
<td>71</td>
<td>Cholangitis</td>
<td>Type II</td>
<td>ES, CBD stents, mechanical lithotripsy</td>
<td>Laparotomy at 11 days</td>
<td>Alive and well</td>
</tr>
<tr>
<td>23</td>
<td>F</td>
<td>58</td>
<td>Jaundice+pain</td>
<td>Type I</td>
<td>CBD stent</td>
<td>OC at 9 days</td>
<td>Liver abscess, treated with antibiotics. Died of multi-organ failure at 18 days</td>
</tr>
<tr>
<td>25</td>
<td>M</td>
<td>62</td>
<td>Pain</td>
<td>Type I</td>
<td>ES done previously for CBD stone. No endoscopic treatment at this time</td>
<td>Awaits surgery</td>
<td>Alive and well</td>
</tr>
</tbody>
</table>
with plastic stents (8) and sphincterotomy (6), extracorporeal shockwave lithotripsy of the gall bladder (1), and adjuvant mechanical lithotripsy (2). Sphincterotomy was avoided in case 17 as she was young, and was not performed for technical reasons in case 15 as the patient had a Polya gastrectomy. Case 23 had stenting without sphincterotomy as the initial diagnosis was thought to be a malignant stricture; however, on review of her imaging Mirizzi's syndrome was diagnosed. Treatment in this group was aimed at relieving jaundice and allowing elective planned cholecystectomy. Surgery was performed at a median time of 15 days after ERCP (range 1–365 days).

Three patients failed to improve after endoscopic therapy: case 23 developed acute cholecystitis, case 14 had persistent cholangitis, and case 22 was operated on for continued haemobilia but surgery failed to identify the source and cholecystectomy was not possible because of severe inflammation of Calot's triangle. This patient subsequently had transcatheter embolisation of a pseudoaneurysm of the cystic artery but although this controlled her haemorrhage she succumbed a week later to multorgan failure. All but one of the patients who had surgery required an open procedure.

Three patients had been treated solely with endoscopic therapy (Table II). Treatment was aimed at relieving jaundice and removing stones. Those in whom complete clearance was not achieved were treated with long term stenting. The stones were completely removed in three patients (cases 2, 6, and 21) using a combination of sphincterotomy, mechanical lithotripsy, methyl tert butyl ether, extracorporeal shockwave lithotripsy, and common duct bile stents. Nine patients were treated with long term stenting and of these five are alive and well at follow up ranging from four months to five years and two months. Four patients in this group died, two of non-biliary causes, another from bronchopneumonia 10 days after ERCP, and one of secondary biliary cirrhosis at two years and seven months. The remaining patient in this group is awaiting extracorporeal shockwave lithotripsy of the gall bladder.

Complications of endoscopic treatment occurred in four of 25 patients: (case 7) bronchopneumonia after ERCP, (case 23) acute cholecystitis after stenting, (case 11) liver abscess treated conservatively with antibiotics, and (case 5) secondary biliary cirrhosis.

The overall mortality of the group was seven of 25, with a 30 day mortality of two of 25. Four of seven deaths were biliary related: (case 5) secondary biliary cirrhosis; (case 7) bronchopneumonia after ERCP; (case 11) carcinoma of gall bladder; (case 22) multiorgan failure secondary to prolonged haemobilia from a pseudoaneurysm of the cystic artery.

Discussion

Mirizzi syndrome, a rare complication of gallstone disease, is increasingly recognised with the widespread availability of cholangiography. In the past the diagnosis was often first made at laparotomy, and because of the severe inflammation in Calot's triangle associated with a shrunken gall bladder, the risk of bile duct injury was high. The syndrome, as originally described, comprised a stone

### Table II: Clinical details of the patients managed solely by endoscopic therapy

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age</th>
<th>Sex</th>
<th>Presentation</th>
<th>Coexistent Illness</th>
<th>Mirizzi type</th>
<th>Endoscopic therapy</th>
<th>No of ERCPs</th>
<th>Duration of inpatient days</th>
<th>Cumulative days</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 F 88</td>
<td></td>
<td>Jaundice+ pain</td>
<td>Cardiac failure, Hypertension</td>
<td>Type II</td>
<td>ES, Mechanical lithotripsy, CBD stents</td>
<td>6</td>
<td>4 years 7 months</td>
<td>13</td>
<td>Long term stenting. Died of CCF, IHD, CVA, non-biliary causes</td>
<td></td>
</tr>
<tr>
<td>2 M 59</td>
<td></td>
<td>Jaundice</td>
<td>Angiina, MI, epilpley, CVA, Pulmonary embolism</td>
<td>Type I</td>
<td>ES, ESWL, GB, MTBE, Mechanical lithotripsy</td>
<td>2</td>
<td>20 days</td>
<td>20</td>
<td>Ducts clear. Alive with no biliary problems</td>
<td></td>
</tr>
<tr>
<td>3 F 84</td>
<td></td>
<td>Jaundice</td>
<td>Ischaemic heart disease</td>
<td>Type I</td>
<td>ES, cystic duct disimected, Mechanical lithotripsy, CBD stents</td>
<td>3</td>
<td>5 years 2 months</td>
<td>33</td>
<td>Long term stenting. Alive and well, no biliary problems</td>
<td></td>
</tr>
<tr>
<td>5 F 78</td>
<td></td>
<td>Jaundice</td>
<td>Diabetes</td>
<td>Type II</td>
<td>ES, Mechanical lithotripsy, ESWL, CBD stents</td>
<td>5</td>
<td>2 years 7 months</td>
<td>19</td>
<td>Long term stenting. Died with secondary biliary cirrhosis</td>
<td></td>
</tr>
<tr>
<td>6 F 63</td>
<td></td>
<td>Jaundice</td>
<td></td>
<td>Type II</td>
<td>ES, Mechanical lithotripsy, ESWL, CBD stents</td>
<td>7</td>
<td>2 years 10 months</td>
<td>16</td>
<td>Ducts clear. Not anxious for surgery. Alive and well at 4 years and 5 months follow up</td>
<td></td>
</tr>
<tr>
<td>7 F 81</td>
<td></td>
<td>Cholangitis</td>
<td>Cardiac failure CVA, Hx PE+DVT, atrial fibrillation</td>
<td>Type II</td>
<td>ES, CBD stent</td>
<td>1</td>
<td>10 days</td>
<td>10</td>
<td>Died of bronchopneumonia 10 days, jaundice was resolving</td>
<td></td>
</tr>
<tr>
<td>10 F 91</td>
<td></td>
<td>Jaundice</td>
<td>CVA, atrial fibrillation</td>
<td>Type II</td>
<td>ES, CBD stent, GB stent</td>
<td>3</td>
<td>2 years 9 months</td>
<td>6</td>
<td>Long term stenting. Alive and well at 2 years 9 months follow up</td>
<td></td>
</tr>
<tr>
<td>13 F 73</td>
<td></td>
<td>Jaundice+ pain</td>
<td>Asthma, chronic anaemia, endometrial Ca, Ischaemic heart disease, CVA</td>
<td>Type I</td>
<td>CBD stent</td>
<td>1</td>
<td>10 months 2 weeks</td>
<td>2</td>
<td>Died of endometrial carcinoma at 10 months. Non-biliary death</td>
<td></td>
</tr>
<tr>
<td>16 F 69</td>
<td></td>
<td>Jaundice</td>
<td></td>
<td>Type I</td>
<td>ES, CBD stent</td>
<td>1</td>
<td>11 months</td>
<td>18</td>
<td>Alive and well. Long term stenting. Not anxious for surgery</td>
<td></td>
</tr>
<tr>
<td>18 F 70</td>
<td></td>
<td>Jaundice</td>
<td></td>
<td>Type I</td>
<td>ES, cystic duct disimected, CBD stent</td>
<td>2</td>
<td>7 months</td>
<td>4</td>
<td>Alive and well. Long term stenting. Not anxious for surgery</td>
<td></td>
</tr>
<tr>
<td>19 M 78</td>
<td></td>
<td>Jaundice+ pain</td>
<td>COAD, hypertension, Paraplegia</td>
<td>Type II</td>
<td>ES, ESWL, CBD stent, URSO</td>
<td>1</td>
<td>4 months</td>
<td>2</td>
<td>Alive and well. Long term stenting</td>
<td></td>
</tr>
<tr>
<td>21 M 80</td>
<td></td>
<td>Jaundice+ pain</td>
<td></td>
<td>Type I</td>
<td>ES, GB decompression, ESWL</td>
<td>10</td>
<td>10 days</td>
<td>10</td>
<td>Discharged with clear ducts at 10 days. Died at 10 months non-biliary causes</td>
<td></td>
</tr>
<tr>
<td>24 M 69</td>
<td></td>
<td>Jaundice</td>
<td></td>
<td>Type II</td>
<td>ES, CBD stent, GB stent</td>
<td>1</td>
<td>1 month</td>
<td>2</td>
<td>Alive and well, awaiting ESWL</td>
<td></td>
</tr>
</tbody>
</table>

MI=myocardial infarction, CVA=cardiovascular accident, DVT=deep venous thrombosis, COAD=chronic obstructive airway disease, MTBE=methyl tert butyl ether, URSO=ursodeoxycholic acid, Hx of PE=pulmonary embolus, CCF=congestive cardiac failure, IHD=ischaemic heart disease.
impacted in the cystic duct or neck of the gall bladder and a functional disorder of a putative sphincter within the common hepatic duct, without any lesion of the common bile duct.\textsuperscript{3} Inflammation, aberrant vessels or an impacted cystic duct stone were thought to stimulate contraction of this ‘sphincter’ resulting in obstructive jaundice. It is now known that such ‘sphincter’ exists and that biliary obstruction results from extrinsic compression of the common duct by the inflamed gall bladder and that the inflammatory process may result in common duct disruption.

In 1982 McSherry\textsuperscript{4} classified Mirizzi’s syndrome into type I and type II based on cholangiographic findings at ERCP. Type I is present when there is extrinsic compression of the common duct by a stone in the gall bladder or in the cystic duct (Fig 1). Type II is present when a choledochocystocholedochal fistula exists (Fig 2). Type II has been further subclassified by Csendes et al\textsuperscript{5} into the atypical endoscopic size of the defect in the common duct – type II: erosion of less than one third the circumference of the bile duct; type III: erosion of up to two thirds of the common duct; type IV: complete destruction of the entire wall of the common duct. The size of the fistula in Csendes’ series was determined at peroperative cholangiography. In our experience exact quantification of fistula size at pre-operative cholangiography is impossible, and we therefore use McSherry’s classification. The importance of recognising type II Mirizzi is stressed as the operative approach differs in the presence of a choledochocystocholedochal fistula. An open surgical approach is considered more appropriate than a laparoscopic approach if a fistula is present as dissection may be difficult and a direct common duct repair or biliary enteric anastomosis is necessary.\textsuperscript{5,6} Indeed an open procedure is often necessary for Mirizzi’s syndrome irrespective of type due to severe inflammation and this is reflected in our series where all but one of our patients who had surgery required an open procedure.

There are a number of published reports of non-surgical management of Mirizzi’s syndrome. Percutaneous management is usually reserved for patients who have failed endoscopic access and who are unsuitable surgical candidates. Cairns\textsuperscript{7} and Oortb\textsuperscript{8} describe percutaneous cholecystodocholithotomy and electrohydraulic lithotripsy, performed under light general anaesthesia, in patients with Mirizzi type I. Adam\textsuperscript{9} used a percutaneous metal stent to decompress the biliary tree in an elderly patient with Mirizzi syndrome, and left the gall stones in situ. This patient was well at follow up at 2-5 years. Endoscopic management of Mirizzi syndrome comprises biliary drainage of the common duct with or without gall bladder drainage, and stone removal with either basket or balloon, mechanical, electrohydraulic or extracorporeal lithotripsy or dissolution therapy. Endoscopic sphincterotomy is followed by either placement of a nasobiliary catheter or more commonly insertion of an indwelling prosthesis into the common bile duct, cystic duct or both.\textsuperscript{10-12} After resolution of jaundice or cholangitis attempts are made to clear the stones when surgery is not deemed appropriate. The largest published series of solely endoscopic management of Mirizzi syndrome is by Binmoeller et al.\textsuperscript{13} In this series electrohydraulic lithotripsy was adopted under cholangioscopic guidance to 14 patients with Mirizzi’s syndrome. In all patients the stone was impacted distally in the cystic duct and stone size ranged from 1-5 cm to greater than 3 cm. Stones were cleared in all 14 patients with only one complication: there was leakage of contrast from the duct system into the peritoneal cavity after removal of a large 3-5 cm stone. This leak was caused by pressure necrosis from the large stone rather than injury to the duct by the electrohydraulic lithotripsy probe and resolved spontaneously with conservative management. The authors conclude that this is a safe and effective treatment with percutaneous drainage, although this technique include the need for considerable expertise at ERCP, cost of equipment including mother and baby scope system, and electrohydraulic lithotribe probe per patient treatment session and the procedure is time consuming. In addition stones must be accessible to the electrohydraulic lithotribe and hence Mirizzi’s syndrome patients with a stone impacted in Hartmann’s pouch are not suitable for this treatment (12 of 25 of our patients).

In our series almost half had definitive surgery after endoscopic therapy. As can be seen from Table I those who were referred for surgery were generally fit patients or patients who did not initially respond to endoscopic drainage (cases 14, 22, and 23). The importance of preliminary cholangiography should be emphasised: the diagnosis was only suspected in one of 25 patients after ultrasound. Cholangiography permits diagnosis, classification of type, and provides a roadmap for subsequent surgery. If ERCP is performed attempts can also be made to dislodge or remove the obliterating calculi at the initial diagnostic procedure. Interestingly in our series only two (case 14 and 22) of the surgically treated group had type II Mirizzi syndrome. Case 14 had an initial ERCP with sphincterotomy and mechanical lithotripsy and partial removal of the obstructing calculus. A stent was left for temporary drainage; however, the patient had persistent cholangitis and was referred for cholecystectomy and common duct exploration. Surgery was difficult as anatomical landmarks were very distorted and there was a large fistula between the shrunken gall bladder and the common duct with no identifiable cystic duct. During dissection a hole was made accidentally in the right main duct. The gall bladder was opened, stone debris was removed from the duct with the endoscopic stent. The gall bladder was not shrunken and the fistula was directly repaired over a T tube. A second T tube was placed across the right hepatic duct defect. The T tubes were removed after a subsequent cholangiogram, which confirmed clear ducts and no biliary leak. Case 22 was a patient who at ERCP for cholangitis was found
to have haemobilia. Sphincterotomy was performed and attempts to remove the large 3 cm calculus with mechanical lithotripsy failed. Two large bore stents were placed for temporary drainage; however, a laparotomy was performed for continued haemorrhage. Surgery proved difficult because of anatomical distortion and bleeding and a cholecystectomy and stone removal were not possible. A T tube was placed in the common duct for drainage. Subsequent selective hepatic artery embolisation was performed of a pseudoaneurysm of the cystic artery and although this controlled her haemorrhage she succumbed to multi-organ failure. Surgery for Mirizzi type II is difficult and may be hazardous and endoscopic management may be preferable in this group as one can avoid the difficult surgical repair of the cholecystocholedochal fistula. Seven of nine patients in this series with Mirizzi type II were treated endoscopically.

The timing between preliminary endoscopic treatment and surgery was very variable in our series (Table I) and reflected patient response to initial biliary drainage as well as surgical waiting lists for elective cholecystectomy. Provided the patient’s symptoms are relieved with initial endoscopic treatment definitive surgical treatment can be postponed until the patient is fit for elective surgery. In patients unsuitable or unwilling to undergo surgery further endoscopic attempts are made to disimpact and remove the stones, using a combination of mechanical lithotripsy, dissolution agents or extracorporeal shockwave lithotripsy. We were successful in doing this in three patients, cases 2 and 21 who were medically unfit and case 6 who refused surgery.

There were nine patients who had long term stenting. The median age of this group was 78 years, range 69–91, and all but one (case 18) had coexistent medical problems making them unsuitable surgical candidates (Table II). Bergman et al.\(^1\) recently reported the outcome of long term stenting in 58 of 117 patients for irretrievable common duct stones and showed a 40% complication rate, most commonly cholangitis, and nine of 44 patients had a biliary related death. The authors conclude that permanent biliary stenting (that is, stent exchange for recurrent symptoms) should be restricted to patients unfit for surgery or further endoscopic therapy and those with a short life expectancy and we agree with this policy. In our unit we change long term stents at yearly intervals but we review patients if they have recurrent symptoms between stent exchanges. Of the nine patients with long term stenting five are alive and well. Of the four who died there was one biliary death (case 5) from secondary biliary cirrhosis. This patient was initially referred for ERCP with suspected primary biliary cirrhosis and Mirizzi’s syndrome was diagnosed. She was a diabetic and not anxious for surgery. She had five ERCPs with mechanical lithotripsy and extracorporeal shock wave lithotripsy, however her stone remained. She was asymptomatic with stenting until finally presenting at two years and seven months with ascites, and oesophageal varices, but without jaundice. She succumbed after gastrointestinal haemorrhage. In retrospect this patient may have had a better outcome had she agreed to surgery. Complications of treatment occurred in a further three patients: bronchopneumonia resulting in the demise of one patient at 10 days; acute cholecystitis after stenting treated surgically; and a liver abscess that was treated conservatively. The latter patient (case 11) had an open cholecystectomy at 116 days and histological examination of her gall bladder revealed an unsuspected gall bladder carcinoma. Coexistence of gall bladder carcinoma and Mirizzi’s syndrome has been recognised previously\(^6\) and is not surprising as both conditions are associated with long term gall stone disease.

In conclusion ERCP plays an important part in diagnosis and provides not only a roadmap for surgery but permits therapeutic decompression of the biliary tree as a temporising measure before surgery. In some patients endoscopic clearance of stones is possible, and long term stenting for those in whom clearance is not achieved is an alternative, effective option to surgery – with the caveat that these patients should be followed up at regular intervals to prevent complications. Finally those patients with Mirizzi type II may be more suited to endoscopic therapy as this can avoid what is often very difficult open surgery.

This work has previously been presented in abstract form at the British Society of Gastroenterology Spring meeting 20–22 March 1996 (Gut 1996; 38 A55).

---

Endoscopic management of Mirizzi's syndrome.

R E England and D F Martin

Gut 1997 40: 272-276
doi: 10.1136/gut.40.2.272

Updated information and services can be found at:
http://gut.bmj.com/content/40/2/272

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections
Pancreas and biliary tract (1949)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/